Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441373 | 1.00 | XDH (0.36) | XDHFAAHADAM17HRH3KCNH2 | |
| SCHEMBL15441228 | 0.92 | XDH (0.37) | XDHFAAHADAM17HRH3KCNH2 | |
| SCHEMBL12988291 | 0.92 | XDH (0.37) | XDHFAAHADAM17HRH3KCNH2 | |
| SCHEMBL12989318 | 0.89 | XDH (0.35) | XDHFAAHADAM17HRH3KCNH2 | |
| SCHEMBL15441961 | 0.89 | XDH (0.35) | XDHFAAHADAM17HRH3KCNH2 | |
| SCHEMBL15420698 | 0.85 | FFAR4 (0.38) | XDHFAAHADAM17AOC3BRD4 | |
| SCHEMBL15441235 | 0.85 | FFAR4 (0.38) | XDHFAAHADAM17AOC3BRD4 | |
| SCHEMBL15420581 | 0.85 | FAAH (0.41) | XDHFAAHADAM17HRH3CXCR1 | |
| SCHEMBL15441277 | 0.85 | XDH (0.38) | XDHADAM17CXCR1CHRM1PDE10A | |
| SCHEMBL15420210 | 0.85 | XDH (0.38) | XDHADAM17CXCR1CHRM1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | XDH 499/4885FAAH 1196/4885ADAM17 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.